AsianScientist (Oct. 14, 2013) – Otsuka Holdings Co., Ltd.’s wholly-owned subsidiary, Otsuka Pharmaceutical Co., Ltd., successfully completed, through its wholly-owned indirect subsidiary Autumn Acquisition Corporation, its acquisition of Astex Pharmaceuticals, Inc. for US$8.50 per share, net to the seller in cash, without interest and less any required withholding taxes.
The acquisition was effected through a tender offer, which was commenced on September 13, 2013, New York time and expired at 12:00 midnight, New York time at the end of October 10, 2013, followed by a merger on October 11, 2013.
The total purchase price of US$866 million is based on the treasury stock calculation method and a tender offer of US$8.50 per share for all outstanding common shares.
As a result of the merger, Astex’s common stock has ceased to be traded on the NASDAQ as of October 11, 2013 and will no longer be listed.
——
Source: Otsuka Holdings Co., Ltd.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
